GLP-1 Drug Market is predicted to reach USD 88.2 billion at a CAGR of 21.00% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global GLP-1 Drug Market”.

The GLP-1 Drug market is estimated to register a CAGR of 21.00% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global GLP-1 Drug market— Eli Lilly and Company, AstraZeneca, Pfizer, Sanofi, GSK, Novo Nordisk, Gan & Lee Pharmaceuticals, Boehringer Ingelheim, Tonghua Dongbao Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd, Shanghai Renhui Biopharmaceutical Co., Ltd., and Shanghai East China Pharmaceutical Machinery Co., Ltd.

GLP 1 Drug Market Highlights

The global GLP-1 Drug market has registered a CAGR of 21.00% during the forecast period and is estimated to reach USD 88.2 billion by 2032.

The requirement for efficient treatments like GLP-1 receptor agonists is expanding because of the rising occurrence of diabetes around the world. Furthermore, a critical obstruction to the market extension of GLP-1 treatment is the accessibility of oral antidiabetic meds, which are frequently simpler to give than injectable GLP-1 drugs. Furthermore, the amazing chance to extend the signs for GLP-1 medications past diabetes to incorporate circumstances, for example, stoutness, non-alcoholic steatohepatitis (NASH), and cardiovascular illnesses, presents critical development potential. Moreover, Gastrointestinal adverse consequences like vomiting, nausea, and diarrhea related to GLP-1 medications can prompt poor patient compliance and therapy cessation.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of GLP-1 Drug market  Research Report 

Segment Analysis

The global GLP-1 Drug market has been segmented based on type and application.

Based on the type, the market is segmented into long-acting GLP-1 drugs and short-acting GLP-1 drugs. The long-acting GLP-1 drug segment was attributed to holding the largest market share in 2023. Long-acting GLP-1 medications can be joined with different classes of antidiabetic prescriptions, like insulin or SGLT-2 inhibitors, to accomplish synergistic impacts and further develop general glycemic control. This adaptability in treatment regimens improves their utility in overseeing type 2 diabetes.

Based on application, the global GLP-1 Drug market has been segmented into type 2 diabetes (T2DM), obesity, non-alcoholic steatohepatitis (NASH), Alzheimer's disease (AD), and cardiovascular and cerebrovascular diseases (CVD). In 2023, the type 2 diabetes (T2DM) segment was anticipated to have the highest market share. GLP-1 medications give an option in contrast to conventional insulin treatment, decreasing the requirement for different everyday infusions and working on drug regimens for patients with T2DM. This decrease in prescription weight can further develop treatment adherence and personal satisfaction.

Regional Analysis

Based on region, the global GLP-1 Drug market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The European GLP-1 Drug market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The GLP-1 Drug market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's GLP-1 Drug market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share. Weight is a significant risk factor for type 2 diabetes, and North America has one of the greatest obesity rates in the world. As GLP-1 medications grow their signs to incorporate the control of obesity, the region presents a huge market potential because of the enormous populace impacted by weight-related conditions. Cardiovascular illness is a main source of morbidity and mortality in North America. GLP-1 medications with demonstrated cardiovascular advantages are strategically situated to address this basic well-being concern, driving interest and market development in the region.

Moreover, the European market has been persistently growing over the forecast period. European medical services frameworks frequently focus on non-insulin treatments for managing diabetes because of their great security profiles and decreased chance of hypoglycemia. GLP-1 medications, with their adequacy and cardiovascular advantages, adjust well to this inclination, driving adoption and market development.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. Governments across Asia Pacific are implementing different medical service changes and drives to address the rising weight of chronic sicknesses, including diabetes. This involves activities to increase accessibility to necessary prescription drugs and encourage preventative healthcare practices, which presents potential for producers of GLP-1 drugs.

Furthermore, the rest of the world's GLP-1 Drug market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's rising rates of obesity. Increasing Indications, Diabetes Prevalence, and the Development of Healthcare Infrastructure are all factors contributing to the market growth.

Key Findings of the Study

• The global GLP-1 Drug market is expected to reach USD 88.2 billion by 2032, at a CAGR of 21.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. Asia Pacific is rising as a center for innovative clinical work in the drug business. Many organizations are directing clinical preliminaries and research studies on GLP-1 medications in the region, prompting expanded mindfulness, acknowledgment, and adoption of these meds.


• Based on Application, the Type 2 Diabetes (T2DM) segment was attributed to holding the largest market in 2023.


• Eli Lilly and Company, AstraZeneca, Pfizer, Sanofi, GSK, Novo Nordisk, Gan & Lee Pharmaceuticals, Boehringer Ingelheim, Tonghua Dongbao Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd, Shanghai Renhui Biopharmaceutical Co., Ltd., and Shanghai East China Pharmaceutical Machinery Co., Ltd. are the key market players.